Boos J - Search Results

1

c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).

Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J. Hotfilder M, et al. Among authors: boos j. Cancer Chemother Pharmacol. 2002 Aug;50(2):167-9. doi: 10.1007/s00280-002-0477-8. Epub 2002 Jun 15. Cancer Chemother Pharmacol. 2002. PMID: 12172985

2

Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.

Boos J, Küpker F, Blaschke G, Jürgens H. Boos J, et al. Cancer Chemother Pharmacol. 1993;33(1):71-6. doi: 10.1007/BF00686026. Cancer Chemother Pharmacol. 1993. PMID: 8269592

3

All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation.

Freund A, Rössig C, Lanvers C, Gescher A, Hohenlöchter B, Jürgens H, Boos J. Freund A, et al. Among authors: boos j. Ann Oncol. 1999 Mar;10(3):335-8. doi: 10.1023/a:1008365714942. Ann Oncol. 1999. PMID: 10355579 Free article.

4

Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL).

Van Valen F, Fulda S, Truckenbrod B, Eckervogt V, Sonnemann J, Hillmann A, Rödl R, Hoffmann C, Winkelmann W, Schäfer L, Dockhorn-Dworniczak B, Wessel T, Boos J, Debatin KM, Jürgens H. Van Valen F, et al. Among authors: boos j. Int J Cancer. 2000 Oct 15;88(2):252-9. doi: 10.1002/1097-0215(20001015)88:2<252::aid-ijc17>3.0.co;2-u. Int J Cancer. 2000. PMID: 11004677

5

PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.

Müller HJ, Beier R, da Palma JC, Lanvers C, Ahlke E, von Schütz V, Gunkel M, Horn A, Schrappe M, Henze G, Kranz K, Boos J. Müller HJ, et al. Among authors: boos j. Cancer Chemother Pharmacol. 2002 Feb;49(2):149-54. doi: 10.1007/s00280-001-0391-5. Epub 2001 Nov 16. Cancer Chemother Pharmacol. 2002. PMID: 11862429

6

Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.

Lanvers-Kaminsky C, Bremer A, Dirksen U, Jürgens H, Boos J. Lanvers-Kaminsky C, et al. Among authors: boos j. Anticancer Drugs. 2006 Jul;17(6):657-62. doi: 10.1097/01.cad.0000215059.93437.89. Anticancer Drugs. 2006. PMID: 16917211

7

Use of PEG-asparaginase in the treatment of patients with solid tumors.

Vieira Pinheiro JP, Lanvers C, Boos J. Vieira Pinheiro JP, et al. Among authors: boos j. Cancer Chemother Pharmacol. 2001 Nov;48(5):421-2. doi: 10.1007/s002800100361. Cancer Chemother Pharmacol. 2001. PMID: 11761462 No abstract available.

8

Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.

Riedemann L, Lanvers C, Deuster D, Peters U, Boos J, Jürgens H, am Zehnhoff-Dinnesen A. Riedemann L, et al. Among authors: boos j. Pharmacogenomics J. 2008 Feb;8(1):23-8. doi: 10.1038/sj.tpj.6500455. Epub 2007 Apr 24. Pharmacogenomics J. 2008. PMID: 17457342

9

Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens.

Würthwein G, Klingebiel T, Krümpelmann S, Metz M, Schwenker K, Kranz K, Lanvers C, Boos J. Würthwein G, et al. Among authors: boos j. Anticancer Drugs. 2002 Jan;13(1):101-10. doi: 10.1097/00001813-200201000-00012. Anticancer Drugs. 2002. PMID: 11914647

10

Therapy of childhood acute myelogenous leukemias.

Vormoor J, Boos J, Stahnke K, Jürgens H, Ritter J, Creutzig U. Vormoor J, et al. Among authors: boos j. Ann Hematol. 1996 Jul;73(1):11-24. doi: 10.1007/s002770050193. Ann Hematol. 1996. PMID: 8695718 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters